Navigation Links
Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
Date:4/12/2013

(PRWEB) April 12, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its high potency capabilities at the 2013 BIO International Convention in Chicago, Illinois on April 22 – 25, 2013, as well as at INTERPHEX 2013 in New York City on April 23 – 25, 2013.

High potent compounds are in the most stringently regulated categories in the industry, so strict adherence to the regulations and progressive modernization is required to manage the associated risks. Patheon has invested significant resources and maintains specialized teams to meet customer and regulatory standards, while maintaining a longstanding commitment to quality and safety. The company’s unique approach allows for high potent compounds to be taken quickly and cost-effectively from formulation to large-scale manufacturing with consistent, proven quality.

Patheon representatives will be available to discuss the company’s high potency capabilities, along with several other key service offerings, at the BIO International Convention (Booth #2370) and INTERPHEX (Booth #4123). More information is available at http://www.patheon.com/Knowledge-Library/Events.aspx.

To schedule a meeting in advance send an email to events(at)patheon(dot)com. All media inquiries or interview requests should be directed to media(at)patheon(dot)com.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule tech
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
11. Selexis SA to Present at Biotech Showcase 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... OMAHA, Neb., April 1, 2011 Transgenomic, ... scientists have completed studies employing the company,s high-sensitivity ... COLD-PCR and BLOCker™-Sequencing.  Results from these studies will ... Research (AACR) meeting in Orlando, Florida, April 2-6, ...
... National Institute of Standards and Technology (NIST) have developed a ... probes used to study nanoscale structures in situ and as ... improve the accuracy of the most precise and delicate nanoscale ... trying to measure the contours of a surface with a ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT ) ... distributor of probiotics products in China, today announced that ... its newly signed U.S. customer. The U.S. ... and formally entered into its agreement with China-Biotics on ...
Cached Biology Technology:Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Getting the point: Real-time monitoring of atomic-microscope probes adjusts for wear 2China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3
(Date:4/23/2014)... in French and German . ... humans and other mammals, the difference between sexes depends on one ... only in males, where the two sexual chromosomes are X and ... ultimately responsible for all the morphological and physiological differences between males ... A very long time ago, the X and Y were identical, ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... (4/23/14) -- Researchers have found evidence of an ... that increase aggressive behavior in children, especially in ... all children exposed to prenatal smoking will have ... not," said Brian Boutwell, Assistant Professor at Sam ... senior author on the study. "One possible ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3Picky male black widow spiders prefer well-fed virgins 2Genetics risk, prenatal smoking may predict behavioral problems 2
... Clonorchis sinensis affects more than 35 million people ... by this parasite causes clonorchiasis. Repeated or chronic infection can ... bile ducts, including the frequently fatal bile duct cancer - ... C. sinensis , published in BioMed Central,s open access journal ...
... researchers found a way of identifying ideal drug combinations ... occurring. The findings, published in Nature Chemical ... development of new drug combinations to combat severe diseases ... stroke and Alzheimer,s are worsened by inflammation, which is ...
... genetically engineered clotting factor that controlled hemophilia in an ... hemophilia and a broad range of other bleeding problems. ... Xa (FXa), a protein active in blood clotting, and ... bleeding in mouse models of hemophilia. "Our designed variant ...
Cached Biology News:Liver parasite lacks key genes for fatty acid synthesis: Genome sequencing of Clonorchis sinensis 2Manchester's 'first step' to perfect drug combinations 2Bioengineered protein shows preliminary promise as new therapy for hemophilia 2
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... imaging software for the microscopy market ... cameras, components and peripherals with powerful ... Its intuitive interface simplifies workflow and ... providing powerful features such as image ...
Biology Products: